Abstract 2439
Background
Tumour infiltrating T cell subsets are associated with a prognosis in gastric cancer (GC). However, there has been no study of T cell subsets on the efficacy of immune checkpoint blockades (ICBs). This study was designed to assess T cell subsets in tumour by using multiplex immunohistochemistry (mIHC) and to evaluate the association of T cell subsets and efficacy of ICBs in patients with GC who received ICBs.
Methods
We assess patients who have treated with ICBs and available tumour tissues before initiation of ICBs. Multiple stainings were performed with different kinds of T cell or immune checkpoint surface markers (CD3, CD4, CD8, PD-L1, PD1, FOXP3, CK, Ki-67, TIM-3, LAG-3, CD45 and CD45RO) in a single section through 12 times-repeated staining-scanning-stripping procedures. Density was defined to be the number of positively-stained cells per mm2.
Results
Eighty-four patients (40 (47.6%) in first- or second-line; 44 (52.4%) in third- or later lines) were analyzed. Patients with MSI-H, EBV and non-MSI/non-EBV were 7 (8.3%), 3 (3.6%) and 74 (88.1%). A high intratumoral CD3+CD8+/CD3+ T cells ratio was associated with better response rate (RR) (34.2% vs 8.8%, p = 0.034) and longer overall survival (OS) (24.3 vs. 5.9 months, p < 0.001). A high CD3+CD8+ density (17.9 vs. 5.9 months, p = 0.001), high stromal CD3+CD4+FOXP3+/CD3+CD4+ T cells ratio (5.5 vs. 2.5 months, p = 0.0001, in PFS), low CD3+CD4+/CD3+ T cells ratio (5.7 vs. 24.3 months, p < 0.001) and low CD3+CD45RO+/CD3+ T cells ratio (7.1 vs. 10.4 months, p = 0.033) were correlated with improved OS. Low CD3+CD4+/CD3+ T cells ratio (33.3% vs. 9.1%, p = 0.041) and high stromal CD3+CD4+Foxp3+/CD3+CD4+ T cells ratio (37.8% vs. 5.7%, p = 0.004) were significantly associated with better tumor response. GC harboring MSI-H and EBV had higher CD3+C8+/CD3+ cells ratio and CD3+CD8+ T cells density than GC with non-MSI/non EBV. Patients with MSI-H and EBV had longer OS than those with non-MSI/non-EBV (not reached to median value, 27.3 months and 7.0 months, p < 0.001).
Conclusions
Composition, density and distribution of T cell subsets in tumour were associated with the response to ICBs. mIHC is a good method to assess T cell subsets in archival tumour tissue.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5203 - Novel fusion genes identified from matched primary and recurred breast cancers by RNA-sequencing
Presenter: Soojeong Choi
Session: Poster Display session 2
Resources:
Abstract
5873 - Association between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer
Presenter: Donna Fitzgerald
Session: Poster Display session 2
Resources:
Abstract
3588 - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: a translational approach.
Presenter: Anna Adam-Artigues
Session: Poster Display session 2
Resources:
Abstract
5640 - Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
Presenter: Marija Balic
Session: Poster Display session 2
Resources:
Abstract
2616 - Clinical application of mutational analysis in breast cancer patients: the relevance of PIK3CA analysis for precision medicine.
Presenter: Juan Miguel Cejalvo
Session: Poster Display session 2
Resources:
Abstract
3870 - A retrospective gene expression analysis of surgically-removed Breast Cancer Brain Metastasis (BCBM)
Presenter: Meritxell Mallafré-Larrosa
Session: Poster Display session 2
Resources:
Abstract
1240 - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: meta-analysis of Phase II and III randomized clinical trials
Presenter: Claudia Omarini
Session: Poster Display session 2
Resources:
Abstract
5535 - Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): management and time course of key adverse events of special interest (AESIs) in SOLAR-1
Presenter: Hope Rugo
Session: Poster Display session 2
Resources:
Abstract
3093 - Changes in Hormone-Receptor status in Luminal breast cancers between primary tumor and metastases: results of the observational cohort GIM-13 AMBRA Study
Presenter: Marina Cazzaniga
Session: Poster Display session 2
Resources:
Abstract
1378 - MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)
Presenter: Miguel Martín
Session: Poster Display session 2
Resources:
Abstract